Metformin and Weight Loss in Patients with Polycystic Ovary Syndrome
Abstract
Introduction: Polycystic ovary syndrome is the most prevalent endocrinopathy in women of reproductive age. One characteristic of this disease is an association with various cardiovascular risk factors, including obesity, overweight, and insulin resistance. It is therefore important to study weight loss associated the use of metformin, which is widely prescribed to patients with polycystic ovary syndrome, in this population. Material and Methods: A systematic review using only randomized clinical trials with placebo or control group using or not lifestyle change measures and systematic reviews. Results: Based on the quality criteria for this review, a total of 14 studies were included and expanded the period of 2011 to 2014. Conclusion: The use of high-dose metformin (>1500 mg per day) is associated with an average weight loss of 2.7 kg in 6 months; however, physical activity and diet were more efficient than metformin alone. When metformin is used in association with hormonal treatment, in the form of the oral contraceptive pill, a slight attenuation in weight loss is observed.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.